Clinical Trial Update: Octreotide LAR as Maintenance Treatment for Patients With NEC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Octreotide LAR as maintenance therapy for neuroendocrine carcinomas in the gastroenteropancreatic and esophageal sites;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Neuroendocrine Carcinoma
• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• Octreotide LAR (octreotide long-acting release)

Snippet

Sponsor: Peking University | Conditions: Gastro-entero-pancreatic Carcinoma, Esophageal Neuroendocrine Carcinoma | Phase 2 | Status: UNKNOWN